Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial

Autor: Natalia López-Andrés, Bengt Fellström, Nicolas Girerd, Madonna Salib, Alan G. Jardine, Roland E. Schmieder, Céline Leroy, Ziad A. Massy, Kevin Duarte, Patrick Rossignol, Hallvard Holdaas, Sophie Girerd, Hubert Scharnagl, Winfried März, Faiez Zannad

Publikováno v: Clinical Research in Cardiology
Clinical Research in Cardiology, Springer Verlag, 2021, ⟨10.1007/s00392-021-01898-9⟩
Clinical Research in Cardiology, 2021, ⟨10.1007/s00392-021-01898-9⟩

Background Biomarkers of fibrosis are associated with outcome in several cardiovascular diseases. However, their relevance to chronic kidney disease and dialysis is uncertain, as it remains unclear how the kidneys and the dialysis procedure itself af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77da843280097acdab79a9ad4552febf
https://hal.univ-lorraine.fr/hal-03272812/document

B-cell depletion or belimumab or voclosporin for lupus nephritis?

Autor: Hans-Joachim Anders, Yutian Lei, Jerome Loutan

Publikováno v: Current opinion in nephrology and hypertension. 30(2)

Purpose of review Despite ground-breaking innovations for most autoimmune diseases, the treatment of lupus nephritis has remained largely the same for decades because none of the tested drugs demonstrated superiority over standard-of-care in randomiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc628356c7e81814073daaa85eda2e68
https://pubmed.ncbi.nlm.nih.gov/33186226

Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial

Autor: Sergei Malikov, Luc Frimat, Patrick Rossignol, Sophie Girerd, Nicolas Girerd, Alan G. Jardine, Faiez Zannad, Bengt Fellström, Nicla Settembre, Roland E. Schmieder, Hallvard Holdaas

Publikováno v: Clinical Kidney Journal
Clinical Kidney Journal, Oxford University Press, 2020, 13 (1), pp.116-122. ⟨10.1093/ckj/sfz048⟩
Clinical Kidney Journal, 2020, 13 (1), pp.116-122. ⟨10.1093/ckj/sfz048⟩

Background The impact of arteriovenous fistula (AVF) or graft (AVG) thrombosis on mortality has been sparsely studied. This study investigated the association between AVF/AVG thrombosis and all-cause and cardiovascular mortality. Methods The data fro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e246259da1a0cc267c77f96b384572b6
https://hal.univ-lorraine.fr/hal-02571720/file/CKJ_2019.pdf

Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis

Autor: Graciela E. Delgado, Bénédicte Stengel, Winfried März, Bengt Fellström, Marie Metzger, Mugurel Apetrii, Sandra Wagner, Roland E. Schmieder, Marcus E. Kleber, Alan G. Jardine, Patrick Rossignol, Hubert Scharnagel, Faiez Zannad, Hallvard Holdaas, Ziad A. Massy

Statin treatment reduces the risk of cardiovascular mortality in the general population, but it has little or no benefit in hemodialyzed (HD) patients. This may reflect different underlying pathophysiology of cardiovascular disease (CVD) in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fdc0735b97edcaf9d1a5fe987d8e610

Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Autor: Gianna Fabbri, Aldo P. Maggioni

Publikováno v: Advances in Therapy. 26:469-487

Abundant evidence from large-scale clinical trials supports the importance of lowering low-density lipoprotein cholesterol (LDL-C) to decrease the risk of cardiovascular disease (CVD) events. The LDL-C targets in various guidelines remain important t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edd275970f52a19cd0be2af4db2e3854
https://doi.org/10.1007/s12325-009-0025-6